Abiopharma

🔍 O'Brien Michael Graham (Executive)

Company: ZoomInfo Technologies Inc. (GTM)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 1,554 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 156,056.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 224 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 156,280.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 765 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 157,045.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 29,400 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 186,445.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 7,813 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 194,258.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Acquired 28,050 shares of Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 222,308.00 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 18,054 shares of Common Stock at $5.98 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 204,254.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,554 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,665.00 | transaction_form_type: 4 | Footnotes: F1, F1, F3, F3
• Sold 224 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 893.00 | transaction_form_type: 4 | Footnotes: F1, F1, F4, F4
• Sold 765 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 4,587.00 | transaction_form_type: 4 | Footnotes: F1, F1, F5, F5
• Sold 7,813 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 78,125.00 | transaction_form_type: 4 | Footnotes: F1, F1, F6, F6
• Sold 28,050 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 56,950.00 | transaction_form_type: 4 | Footnotes: F1, F1, F7, F7

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock.
• F2: Reflects shares withheld to cover the Reporting Person's tax liability in connection with the vesting of the restricted stock units reported herein.
• F3: The Reporting Person received an original grant of restricted stock units on December 30, 2022, which vest in equal quarterly installments during the 27 months following October 1, 2024.
• F4: The Reporting Person received an original grant of restricted stock units on March 23, 2023, which vest in equal quarterly installments during the 30 months following October 1, 2024.
• F5: The Reporting Person received an original grant of restricted stock units on October 25, 2023, which vest in equal quarterly installments during the 36 months following October 1, 2024.
• F6: The Reporting Person received an original grant of restricted stock units on September 10, 2024, which vest as follows: (a) 25% on October 1, 2025; and (b) the remainder of the award in equal quarterly installments during the 36 months following October 1, 2025.
• F7: The Reporting Person received an original grant of restricted stock units on May 15, 2025, which vests as follows: (a) 33% on May 15, 2026; and (b) the remainder of the award in equal quarterly installments during the 24 months following May 15, 2026.